Isodiol International Inc. (CSE:ISOL) (OTC:LAGBF) (Frankfurt:LB6A.F) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned subsidiary for the period from April 1, 2017 to June 30, 2017.
Mounting research from around the world suggests marijuana's potential to treat multiple medical conditions ranging from chronic pain to cancer, epilepsy, HIV/AIDS, anxiety and more.
Investing in marijuana seems to be the current trend as high returns have been noted across the board, however, Investors have, in the past year, been spoiled by incredibly high yields since the stock market’s bounce back after 2008. The three major U.S. indexes have tripled in value, with the NASDAQ Composite reaching almost four times what it was in 2009.
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA).
Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) announced today that common shares of the Company will commence trading on Toronto Stock Exchange (the "TSX") effective Monday July 24 . Common shares will continue to trade under the symbol "ACB".
Lotus Ventures Inc. (“Lotus” or the “Company”) (CSE:J) is pleased to announce a non-brokered private placement offering (the “Offering”), the start of facility construction, provide details on its streaming agreement with Cannabis Wheaton Income Corp. (“CBW”) and an update on the regulatory licensing process.
Aaron Keay, CEO of ABcann Global Corporation, speaks with Natasha Frakes about why the company waited two years from getting their license before going public.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”).
According to a research report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% from 2017 to 2024. By 2024, the projected demand of cannabis will continue to rise for both recreational and medical use, while reaching an estimated global sales value of $63.5 billion .
India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its financial results for the fiscal year ended March 31, 2017.
SANTA ANA, Calif. Kush Bottles, Inc. (OTCQB: KSHB), a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry, today reported financial results for its third fiscal quarter ended May 31, 2017 .
A better than expected quarter has Clarus analyst Noel Atkinson raising his price target on Aphria (TSXV:APH).
On Wednesday, Aphria reported its Q4 and fiscal 2017 results. In the fourth quarter, the company lost $2.6-million on revenue of $5.7-million, a topline that was up 106 per cent over the same period last year.
The Company expects to benefit from being listed on the OTCQB and the FSE by gaining greater visibility and convenience of trading the Company’s common shares to US and European investors, allowing a much larger potential shareholder base and enhanced liquidity.
Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , today announced that the second quarter of 2017 generated the largest revenue quarter in the Company's history. Additionally, the Company celebrated the largest-ever single month of revenue in June 2017 as well as the largest sales month and quarter for wholly owned subsidiary Kannaway.
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models.
